Abstract
Neuropeptide Y targets the Y1 receptor (Y1) in the spinal dorsal horn (DH) to produce endogenous and exogenous analgesia. DH interneurons that express Y1 (Y1-INs; encoded by Npy1r ) are necessary and sufficient for neuropathic hypersensitivity after peripheral nerve injury. However, as Y1-INs are heterogenous in composition in terms of morphology, neurophysiological characteristics, and gene expression, we hypothesized that a more precisely defined subpopulation mediates neuropathic hypersensitivity. Using fluorescence in situ hybridization, we found that Y1-INs segregate into 3 largely nonoverlapping subpopulations defined by the coexpression of Npy1r with gastrin-releasing peptide ( Grp / Npy1r ), neuropeptide FF ( Npff / Npy1r ), and cholecystokinin ( Cck / Npy1r ) in the superficial DH of mice, nonhuman primates, and humans. Next, we analyzed the functional significance of Grp / Npy1r , Npff / Npy1r , and Cck / Npy1r INs to neuropathic pain using a mouse model of peripheral nerve injury. We found that chemogenetic inhibition of Npff / Npy1r -INs did not change the behavioral signs of neuropathic pain. Further, inhibition of Y1-INs with an intrathecal Y1 agonist, [Leu 31 , Pro 34 ]-NPY, reduced neuropathic hypersensitivity in mice with conditional deletion of Npy1r from CCK-INs and NPFF-INs but not from GRP-INs. We conclude that Grp / Npy1r -INs are conserved in higher order mammalian species and represent a promising and precise pharmacotherapeutic target for the treatment of neuropathic pain.
Funding Information
  • Office of Extramural Research (T32NS073548, F31NS117054, F99NS124190, R01DA37621, R01NS45954, R01NS62306, R01NS096705)
  • Wellcome Trust (102645/Z/13/Z)